KALA

KALA BIO Inc

KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.

The firm stated that its KPI-012 failed in a mid-stage clinical trial and announced that it intends to preserve cash, including by laying off some of its workforce and deploying other cost-saving measures.

The mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

KALA, GHM, ARQ, and HWKN are drawing investor attention after fresh analyst coverage highlights improving outlooks.

New analyst coverage lifts investor interest in KALA, GHM, ARQ, and HWKN as markets grapple with rising volatility.

Kala is set to report mid-stage trial data in the second quarter for KPI-012, its experimental treatment for persistent corneal epithelial defects.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips KALA stock results show that Kala Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. The post...

Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44...

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash...